Tianjin First Central Hospital
Clinical trials sponsored by Tianjin First Central Hospital, explained in plain language.
-
Can donor immune cells boost lung cancer remission?
Disease control Recruiting nowThis trial is for people with extensive-stage small cell lung cancer who have completed initial chemotherapy plus immunotherapy and have stable or improved disease. Participants are randomly assigned to receive either standard immunotherapy alone or immunotherapy combined with in…
Phase: PHASE2 • Sponsor: Tianjin First Central Hospital • Aim: Disease control
Last updated Aug 14, 2026 00:00 UTC
-
Engineered virus targets Hard-to-Treat cancers from the inside
Disease control Recruiting nowThis study tests an experimental therapy called YH02, a genetically modified virus designed to infect and destroy cancer cells. It is given as an injection directly into tumors in people with advanced solid tumors (such as head and neck cancer, breast cancer, or melanoma) that ha…
Phase: PHASE2 • Sponsor: Tianjin First Central Hospital • Aim: Disease control
Last updated Jul 15, 2026 00:00 UTC
-
New pain combo aims to get bowels moving faster after surgery
Symptom relief Recruiting nowThis study tests whether a combination of a long-lasting numbing drug (liposomal bupivacaine) injected into the belly wall plus a special painkiller (oxycodone) given through an IV can help the gut recover faster after major abdominal surgery. 132 adults having small bowel or col…
Phase: NA • Sponsor: Tianjin First Central Hospital • Aim: Symptom relief
Last updated Jun 27, 2026 14:02 UTC
-
New painkiller may offer longer relief after gallbladder surgery
Symptom relief Recruiting nowThis study tests whether a long-acting painkiller (liposomal bupivacaine) works better than a standard one (ropivacaine) for pain after gallbladder removal. About 86 adults having laparoscopic cholecystectomy will receive one of the two drugs via a nerve block during surgery. Res…
Phase: NA • Sponsor: Tianjin First Central Hospital • Aim: Symptom relief
Last updated Jun 27, 2026 12:32 UTC